Search - tctmd.com

Displaying 281 - 300 of 1215

Sort: Relevancy | Date

News Conference News TCT 2015

Keynote: Simplified Trials, Community Engagement Key to Reinvention of Clinical Research

October 13, 2015

News Conference News TCT 2015

Experts Say ‘Big Data’ Represents Future of Health Care Research

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

Current State of Percutaneous Valve Therapies for Use in Congestive HF Explored

October 13, 2015

News Industry News

Clinical Trial Confirms No Late Benefit For Routine Thrombus Aspiration In Stemi Patients

October 13, 2015

Presentation TCT 2015

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Clinician's Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Eric R. Bates

October 12, 2015

Presentation TCT 2015

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Trialist/Guideline Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, John A. Bittl

October 12, 2015

Presentation TCT 2015

A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention

Presenter: Shigeru Saito, Gregg W. Stone, Ron Waksman, Shigeru Saito

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Conference News TCT 2015

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

Presentation TCT 2015

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Presenter: Stuart J. Pocock, Jan Tijssen, John L. Petersen

October 11, 2015

News Conference News TCT 2015

Novel Devices Present New Treatment Options for STEMI

Yael L. Maxwell

October 11, 2015

News Conference News TCT 2015

Global TAVR Market Poised to Exceed DES Market by 2025

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Featured Fellow

Ashraf Alazzoni, MD

Yael L. Maxwell

October 09, 2015

Advertisement

Keynote: Simplified Trials, Community Engagement Key to Reinvention of Clinical Research

Experts Say ‘Big Data’ Represents Future of Health Care Research

Discussion Highlights Merits, Limitations of Small Trials

Current State of Percutaneous Valve Therapies for Use in Congestive HF Explored

Clinical Trial Confirms No Late Benefit For Routine Thrombus Aspiration In Stemi Patients

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Clinician's Perspective

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Trialist/Guideline Perspective

A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Novel Devices Present New Treatment Options for STEMI

Global TAVR Market Poised to Exceed DES Market by 2025

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Ashraf Alazzoni, MD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content